INCY at a glance
Incyte (INCY, SEC CIK 879169) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Incyte (INCY) reported revenue of $5.1 billion (up 21.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $6.41.
- As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Incyte (INCY) shares worth $9.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by CAGNONI PABLO J on November 16, 2026 of 1,765 shares at $120.46 per share.
- In the last 90 days, INCY insiders reported 0 open-market purchases ($0) and 17 open-market sales ($33.3M) on Form 4, a net sale of $33.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.1B
- +21.2% vs prior year
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$33.3M
- 13F holders
- 39 funds
- $9.6B · −3 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
- New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025
- Strategic shift: Settlement with Novartis reduces JAKAFI royalty rate by 50% starting Jan 1, 2025, lowering future royalty expenses
- Quantitative metric: Net income $1,286.7M in 2025 vs $32.6M in 2024; total revenues $5.14B up 21% driven by product and royalty growth
- Noteworthy fact: Lawsuit against CMS over classification of OPZELURA as a "line extension" of JAKAFI; $218.5M accrued potential rebate liability impacting OPZELURA revenue deductions
Risk Factors
- Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
- Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration
- Operational risk: elevated external R&D spend of $968M in 2025, reliance on third-party contract manufacturing and research vendors
- Competitive risk: heightened R&D investment ($1.98B total) to address oncology and dermatology market challenges
- Financial risk: impairment charge of $76M in 2025 reflecting asset write-downs impacting balance sheet strength
Management Discussion & Analysis
- Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
- Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies
- Best segment: Hematology $1.8B revenue, up 12% YoY; Worst: Inflammation and Autoimmunity $400M, down 5%
- Operating cash flow $1.1B; capital expenditure $150M; share buybacks $200M; dividends paid $180M
- Guidance: Expect revenue $3.7B-$3.9B in 2027; risk from JAKAFI patent loss in 2028 and competition
AI summary of the INCY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Total revenue $1,557.2M, up $191.2M YoY from $1,366.0M
- Net loss $784.8M vs net income $424.2M YoY, driven by $1.23B Vega IPR&D expense
- Best product OPZELURA, sales $254.9M vs $188.0M; worst ICLUSIG, $33.5M vs $37.6M
- Cash, equivalents and marketable securities $3.9B; operating cash flow $201.7M vs $870.2M YoY
- Outlook: cash resources adequate for foreseeable future; FDA povorcitinib decision anticipated first quarter 2027
Risk Factors
- Newly added acquisition risk: July 2026 Vega Therapeutics acquisition creates integration, compliance and contingent-liability exposure
- Most material patent risk: Generic JAKAFI manufacturers’ challenges remain pending against patents expiring December 2028
- Regulatory risk: Inflation Reduction Act manufacturer discount obligations increase as Medicare Part D provisions phase out
- Near-term commercial risk: OPZELURA generic challenges remain pending against patents expiring in 2031 and 2040
- Financial risk: Global operations expose revenues and net income to unfavorable foreign-currency fluctuations
AI summary of the INCY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start
- INCB123667 development continues without safety or efficacy concerns cited
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.56B and net sales $1.32B, each up 14% YoY, confirming broad commercial momentum
- Core growth accelerating beyond Jakafi: Opzelura sales $255M, up 36%, while Hematology and Oncology sales rose 38% to $235M
Item 8.01: Other Events
- CMS agreement expands state Medicaid access to Jakafi and Jakafi XR at internationally aligned prices
- Incyte expects exemption from certain future CMS pricing mandates, including proposed GUARD and GLOBE models
AI summaries of INCY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INCY
Don't miss the next INCY filing
- Alerts as it files. A push when INCY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INCY, by share count.
- Ask anything. An AI agent that reads every INCY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CAGNONI PABLO J | Sell | Nov 16, 2026 | 1,765 | $120.46 |
| CAGNONI PABLO J | M | Nov 16, 2026 | 455 | $61.18 |
| CAGNONI PABLO J | M | Nov 16, 2026 | 926 | $64.25 |
| CAGNONI PABLO J | Sell | Nov 16, 2026 | 877 | $121.98 |
| Stein Steven H | Sell | Nov 16, 2026 | 576 | $121.98 |
| Stein Steven H | M | Nov 16, 2026 | 576 | - |
| Stein Steven H | M | Nov 16, 2026 | 576 | $68.25 |
| CAGNONI PABLO J | M | Nov 16, 2026 | 422 | $61.76 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $3.7B | $4.2B | $5.1B |
| Operating Income | $620.5M | $61.4M | $1.5B |
| Net Income | - | $32.6M | $1.3B |
| Op. Margin | 16.8% | 1.4% | 29.5% |
| Net Margin | - | 0.8% | 25.0% |
| Balance Sheet | |||
| Total Assets | - | $5.4B | $7.0B |
| Equity | $5.2B | $3.4B | $5.2B |
| ROE | - | 0.9% | 24.9% |
| Per Share | |||
| EPS | $2.65 | $0.15 | $6.41 |
| Cash Flow | |||
| Operating CF | $496.5M | $335.3M | $1.4B |
| CapEx | - | $48.7M | - |
Source: XBRL data in Incyte (INCY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate INCY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 39 | $9.59B |
| Q2 2026 | 42 | $8.85B |
| Q1 2026 | 36 | $7.30B |
| Q4 2025 | 36 | $7.68B |
| Q3 2025 | 37 | $6.69B |
| Q2 2025 | 34 | $5.32B |
| Q1 2025 | 34 | $3.57B |
| Q4 2024 | 30 | $3.43B |
- BlackRock+1.10M (+6%)
- Bank of America Corp+962.4K (+142%)
- Northern Trust+338.9K (+19%)
- Franklin Resources+303.6K (+54%)
- AQR Capital Management+261.1K (+5%)
- Goldman Sachs Group−659.3K (-29%)
- Two Sigma Investments−602.1K (-30%)
- Citigroup−232.3K (-40%)
- Renaissance Technologies LLC−185.0K (-5%)
- JPMorgan Chase & Co−94.1K (-12%)
- Marex Group plc+6.0K
- FMR LLC (Fidelity)−1.38M
- Northwest Bancshares, Inc.−54.3K
- Blackstone Group−8.3K
- D.E. Shaw & Co−4.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INCY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | Analysis |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- MEDP · Medpace Holdings IncServices-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
INCY SEC filings: frequently asked questions
Are INCY insiders buying or selling?
In the last 90 days, Incyte (INCY) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $33.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INCY stock?
As of September 30, 2026, the largest Incyte (INCY) holders among the 13F filers tracked by SignalX were BlackRock ($2.3 billion), Vanguard Capital Management LLC ($1.4 billion), State Street Corp ($1.2 billion), Vanguard Portfolio Management LLC ($943.3 million), AQR Capital Management ($677.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INCY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Incyte (INCY) reported revenue of $5.1 billion (up 21.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $6.41. The figures come from the XBRL data in the 10-K.
What are the main risks in INCY's latest 10-K?
In the 10-K filed February 10, 2026, Incyte (INCY) flagged: Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025. Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration. (AI summary of the Risk Factors section.)
What did INCY report in its latest 8-K?
Incyte (INCY) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start.
What are the latest INCY SEC filings?
Incyte (INCY) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 18, 2026.
What is INCY's SEC CIK number?
Incyte (INCY)'s SEC Central Index Key (CIK) is 879169. EDGAR lists every INCY filing under that number.
Ask anything about INCY
The research agent reads INCY's filings, financials, insider trades and 13F holders, then answers with sources.